403 related articles for article (PubMed ID: 33864801)
1. Association of Plasmodium falciparum kelch13 R561H genotypes with delayed parasite clearance in Rwanda: an open-label, single-arm, multicentre, therapeutic efficacy study.
Uwimana A; Umulisa N; Venkatesan M; Svigel SS; Zhou Z; Munyaneza T; Habimana RM; Rucogoza A; Moriarty LF; Sandford R; Piercefield E; Goldman I; Ezema B; Talundzic E; Pacheco MA; Escalante AA; Ngamije D; Mangala JN; Kabera M; Munguti K; Murindahabi M; Brieger W; Musanabaganwa C; Mutesa L; Udhayakumar V; Mbituyumuremyi A; Halsey ES; Lucchi NW
Lancet Infect Dis; 2021 Aug; 21(8):1120-1128. PubMed ID: 33864801
[TBL] [Abstract][Full Text] [Related]
2. Emergence and clonal expansion of in vitro artemisinin-resistant Plasmodium falciparum kelch13 R561H mutant parasites in Rwanda.
Uwimana A; Legrand E; Stokes BH; Ndikumana JM; Warsame M; Umulisa N; Ngamije D; Munyaneza T; Mazarati JB; Munguti K; Campagne P; Criscuolo A; Ariey F; Murindahabi M; Ringwald P; Fidock DA; Mbituyumuremyi A; Menard D
Nat Med; 2020 Oct; 26(10):1602-1608. PubMed ID: 32747827
[TBL] [Abstract][Full Text] [Related]
3. High Prevalence of Plasmodium falciparum K13 Mutations in Rwanda Is Associated With Slow Parasite Clearance After Treatment With Artemether-Lumefantrine.
Straimer J; Gandhi P; Renner KC; Schmitt EK
J Infect Dis; 2022 Apr; 225(8):1411-1414. PubMed ID: 34216470
[TBL] [Abstract][Full Text] [Related]
4. Trends of Plasmodium falciparum molecular markers associated with resistance to artemisinins and reduced susceptibility to lumefantrine in Mainland Tanzania from 2016 to 2021.
Bakari C; Mandara CI; Madebe RA; Seth MD; Ngasala B; Kamugisha E; Ahmed M; Francis F; Bushukatale S; Chiduo M; Makene T; Kabanywanyi AM; Mahende MK; Kavishe RA; Muro F; Mkude S; Mandike R; Molteni F; Chacky F; Bishanga DR; Njau RJA; Warsame M; Kabula B; Nyinondi SS; Lucchi NW; Talundzic E; Venkatesan M; Moriarty LF; Serbantez N; Kitojo C; Reaves EJ; Halsey ES; Mohamed A; Udhayakumar V; Ishengoma DS
Malar J; 2024 Mar; 23(1):71. PubMed ID: 38461239
[TBL] [Abstract][Full Text] [Related]
5. Expansion of artemisinin partial resistance mutations and lack of histidine rich protein-2 and -3 deletions in Plasmodium falciparum infections from Rukara, Rwanda.
Schreidah C; Giesbrecht D; Gashema P; Young NW; Munyaneza T; Muvunyi CM; Thwai K; Mazarati JB; Bailey JA; Juliano JJ; Karema C
Malar J; 2024 May; 23(1):150. PubMed ID: 38755607
[TBL] [Abstract][Full Text] [Related]
6. Day 3 parasitemia and Plasmodium falciparum Kelch 13 mutations among uncomplicated malaria patients treated with artemether-lumefantrine in Adjumani district, Uganda.
Angwe MK; Mwebaza N; Nsobya SL; Vudriko P; Dralabu S; Omali D; Tumwebaze MA; Ocan M
PLoS One; 2024; 19(6):e0305064. PubMed ID: 38837973
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic efficacy of artesunate-amodiaquine and artemether-lumefantrine and polymorphism in Plasmodium falciparum kelch13-propeller gene in Equatorial Guinea.
Riloha Rivas M; Warsame M; Mbá Andeme R; Nsue Esidang S; Ncogo PR; Phiri WP; Oki Eburi C; Edú Maye CE; Menard D; Legrand E; Berzosa P; Garcia L; Lao Seoane AK; Ntabangana SC; Ringwald P
Malar J; 2021 Jun; 20(1):275. PubMed ID: 34158055
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of artesunate-amodiaquine and artemether-lumefantrine for uncomplicated Plasmodium falciparum malaria in Madagascar, 2018.
Dentinger CM; Rakotomanga TA; Rakotondrandriana A; Rakotoarisoa A; Rason MA; Moriarty LF; Steinhardt LC; Kapesa L; Razafindrakoto J; Svigel SS; Lucchi NW; Udhayakumar V; Halsey ES; Ratsimbasoa CA
Malar J; 2021 Nov; 20(1):432. PubMed ID: 34732201
[TBL] [Abstract][Full Text] [Related]
9. Surveillance of artemether-lumefantrine associated Plasmodium falciparum multidrug resistance protein-1 gene polymorphisms in Tanzania.
Kavishe RA; Paulo P; Kaaya RD; Kalinga A; van Zwetselaar M; Chilongola J; Roper C; Alifrangis M
Malar J; 2014 Jul; 13():264. PubMed ID: 25007802
[TBL] [Abstract][Full Text] [Related]
10. Novel pfkelch13 Gene Polymorphism Associates With Artemisinin Resistance in Eastern India.
Das S; Manna S; Saha B; Hati AK; Roy S
Clin Infect Dis; 2019 Sep; 69(7):1144-1152. PubMed ID: 30535043
[TBL] [Abstract][Full Text] [Related]
11. Absence of in vivo selection for K13 mutations after artemether-lumefantrine treatment in Uganda.
Balikagala B; Mita T; Ikeda M; Sakurai M; Yatsushiro S; Takahashi N; Tachibana SI; Auma M; Ntege EH; Ito D; Takashima E; Palacpac NM; Egwang TG; Onen JO; Kataoka M; Kimura E; Horii T; Tsuboi T
Malar J; 2017 Jan; 16(1):23. PubMed ID: 28068997
[TBL] [Abstract][Full Text] [Related]
12. Modeling policy interventions for slowing the spread of artemisinin-resistant pfkelch R561H mutations in Rwanda.
Zupko RJ; Nguyen TD; Ngabonziza JCS; Kabera M; Li H; Tran TN; Tran KT; Uwimana A; Boni MF
Nat Med; 2023 Nov; 29(11):2775-2784. PubMed ID: 37735560
[TBL] [Abstract][Full Text] [Related]
13. Selection of Plasmodium falciparum pfcrt and pfmdr1 polymorphisms after treatment with artesunate-amodiaquine fixed dose combination or artemether-lumefantrine in Liberia.
Otienoburu SD; Maïga-Ascofaré O; Schramm B; Jullien V; Jones JJ; Zolia YM; Houzé P; Ashley EA; Kiechel JR; Guérin PJ; Le Bras J; Houzé S
Malar J; 2016 Sep; 15(1):452. PubMed ID: 27596849
[TBL] [Abstract][Full Text] [Related]
14. Spatio-temporal distribution of PfMDR1 polymorphism among uncomplicated Plasmodium falciparum malaria cases along international border of north east India.
Goomber S; Mishra N; Anvikar A; Yadav CP; Valecha N
Infect Genet Evol; 2018 Sep; 63():285-290. PubMed ID: 29842979
[TBL] [Abstract][Full Text] [Related]
15. Polymorphisms in Plasmodium falciparum chloroquine resistance transporter and multidrug resistance 1 genes: parasite risk factors that affect treatment outcomes for P. falciparum malaria after artemether-lumefantrine and artesunate-amodiaquine.
Venkatesan M; Gadalla NB; Stepniewska K; Dahal P; Nsanzabana C; Moriera C; Price RN; Mårtensson A; Rosenthal PJ; Dorsey G; Sutherland CJ; Guérin P; Davis TME; Ménard D; Adam I; Ademowo G; Arze C; Baliraine FN; Berens-Riha N; Björkman A; Borrmann S; Checchi F; Desai M; Dhorda M; Djimdé AA; El-Sayed BB; Eshetu T; Eyase F; Falade C; Faucher JF; Fröberg G; Grivoyannis A; Hamour S; Houzé S; Johnson J; Kamugisha E; Kariuki S; Kiechel JR; Kironde F; Kofoed PE; LeBras J; Malmberg M; Mwai L; Ngasala B; Nosten F; Nsobya SL; Nzila A; Oguike M; Otienoburu SD; Ogutu B; Ouédraogo JB; Piola P; Rombo L; Schramm B; Somé AF; Thwing J; Ursing J; Wong RPM; Zeynudin A; Zongo I; Plowe CV; Sibley CH; Asaq Molecular Marker Study Group
Am J Trop Med Hyg; 2014 Oct; 91(4):833-843. PubMed ID: 25048375
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of molecular markers of artemisinin and lumefantrine resistance among patients with uncomplicated Plasmodium falciparum malaria in three provinces in Angola, 2015.
Ljolje D; Dimbu PR; Kelley J; Goldman I; Nace D; Macaia A; Halsey ES; Ringwald P; Fortes F; Udhayakumar V; Talundzic E; Lucchi NW; Plucinski MM
Malar J; 2018 Feb; 17(1):84. PubMed ID: 29458380
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria and prevalence of molecular markers associated with artemisinin and partner drug resistance in Uganda.
Ebong C; Sserwanga A; Namuganga JF; Kapisi J; Mpimbaza A; Gonahasa S; Asua V; Gudoi S; Kigozi R; Tibenderana J; Bwanika JB; Bosco A; Rubahika D; Kyabayinze D; Opigo J; Rutazana D; Sebikaari G; Belay K; Niang M; Halsey ES; Moriarty LF; Lucchi NW; Souza SSS; Nsobya SL; Kamya MR; Yeka A
Malar J; 2021 Dec; 20(1):484. PubMed ID: 34952573
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of arps10, fd, pfmdr-2, pfcrt and pfkelch13 gene mutations in Plasmodium falciparum parasite population in Uganda.
Ocan M; Ashaba FK; Mwesigwa S; Edgar K; Kamya MR; Nsobya SL
PLoS One; 2022; 17(5):e0268095. PubMed ID: 35511795
[TBL] [Abstract][Full Text] [Related]
19. Temporal trends of molecular markers associated with artemether-lumefantrine tolerance/resistance in Bagamoyo district, Tanzania.
Malmberg M; Ngasala B; Ferreira PE; Larsson E; Jovel I; Hjalmarsson A; Petzold M; Premji Z; Gil JP; Björkman A; Mårtensson A
Malar J; 2013 Mar; 12():103. PubMed ID: 23506218
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of artemether-lumefantrine and dihydroartemisinin-piperaquine and prevalence of molecular markers of anti-malarial drug resistance in children in Togo in 2021.
Dorkenoo AM; Warsame M; Ataba E; Hemou M; Yakpa K; Sossou E; Mitigmsagou M; Teou CD; Caspar E; Ma L; Djadou KE; Atcha-Oubou T; Rasmussen C; Menard D
Malar J; 2024 Apr; 23(1):92. PubMed ID: 38570791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
